文献速递妇科生殖医学

IVF对子宫内膜非典型增生或1级腺癌保留生育治疗后复发风险的影响

IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.
PubMed 文献 · Reprod Biomed Online · 2021-06-16

IVF组2年复发概率为37.7%(SD 10.41%),非IVF组为55.7%(SD 14.02%),差异无统计学意义(P=0.13)。妊娠是复发的保护因素,妊娠组与非妊娠组2年复发概率分别为20.5%和62.0%(P=0.002,95%CI 0.06-0.61)。

要点

  • 保留生育治疗后接受IVF不增加子宫内膜非典型增生或1级腺癌的复发风险。
  • 妊娠与更低的2年复发概率相关(20.5% vs 62.0%,P=0.002)。
  • 缓解后总体复发率较高,应进行密切监测。

核心结论

  • 子宫内膜非典型增生或1级腺癌保留生育治疗缓解后行IVF不增加复发风险,是可接受的缩短妊娠时间的策略。
  • 妊娠是复发的保护因素。
  • 缓解后总体复发率较高,值得密切监测。

研究设计与样本

  • 前瞻性队列研究,数据来自2008年1月至2019年7月的全国登记系统。
  • 缓解后31例接受IVF,29例未接受。
  • 主要结局为根据是否使用IVF的24个月复发率,次要结局为复发危险因素。

主要发现

  • IVF组2年复发概率37.7%(SD 10.41%),非IVF组55.7%(SD 14.02%),P=0.13。
  • 肥胖、未产、多囊卵巢综合征、年龄及肿瘤特征与复发无关。
  • 妊娠组与非妊娠组2年复发概率分别为20.5%和62.0%(P=0.002,95%CI 0.06-0.61)。
  • IVF亚组中周期数、卵巢刺激最大血清雌二醇浓度、刺激方案、促性腺激素总剂量及内膜厚度在复发风险上无显著差异。

关键数值与推荐

  • 2年复发概率:IVF组37.7%(SD 10.41%),非IVF组55.7%(SD 14.02%),P=0.13。
  • 2年复发概率:妊娠组20.5%,非妊娠组62.0%,P=0.002,95%CI 0.06-0.61。

临床怎么用

  • 对子宫内膜非典型增生或1级腺癌保留生育治疗缓解后有生育需求者,可考虑IVF以缩短妊娠时间。
  • 缓解后应密切监测复发,因总体复发率较高。
  • 妊娠可能降低复发风险,应鼓励在缓解后积极实现妊娠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Do IVF treatments after conservative management of endometrial atypical hyperplasia or grade 1 endometrial adenocarcinoma (AH/EC) increase the risk of disease recurrence? DESIGN: This is a prospective cohort study from a national registry from January 2008 to July 2019. Sixty patients had an AH/EC and received progestin treatment using chlormadinone acetate for at least 3 months. After remission, 31 patients underwent IVF and 29 did not. The primary outcome was the recurrence rate at 24 months according to the use of IVF. The secondary outcome was the identification of risk factors for recurrence. RESULTS: The probability of 2-year recurrence was 37.7% (SD 10.41%) in the IVF group and 55.7% (SD 14.02%) in the no IVF group (P = 0.13). Obesity, nulliparity, polycystic ovary syndrome, age and tumoural characteristics were not associated with recurrence. Pregnancy was a protective factor for recurrence, with 2-year recurrence probabilities of 20.5% and 62.0% in the pregnancy and no pregnancy groups, respectively (P = 0.002, 95% CI 0.06-0.61). In contrast, the number of cycles, maximum serum oestradiol concentration during ovarian stimulation, ovarian stimulation protocol, total dose of gonadotrophin administered and thickness of the endometrium showed no significant differences in terms of the risk of recurrence in the IVF subgroup. CONCLUSION: IVF treatment after fertility-sparing management of AH/EC does not increase the risk of recurrence. Therefore, it is an acceptable strategy to decrease the time to pregnancy. Overall, the recurrence rate is high enough to justify close monitoring once remission occurs.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Vaugon M, Peigné M, Phelippeau J, et al. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management. Reprod Biomed Online. 2021. PMID: 34315696. doi:10.1016/j.rbmo.2021.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。